Literature DB >> 33482842

pH-responsive antibodies for therapeutic applications.

Tomasz Klaus1, Sameer Deshmukh2.   

Abstract

Therapeutic antibodies are instrumental in improving the treatment outcome for certain disease conditions. However, to enhance their efficacy and specificity, many efforts are continuously made. One of the approaches that are increasingly explored in this field are pH-responsive antibodies capable of binding target antigens in a pH-dependent manner. We reviewed suitability and examples of these antibodies that are functionally modulated by the tumor microenvironment. Provided in this review is an update about antigens targeted by pH-responsive, sweeping, and recycling antibodies. Applicability of the pH-responsive antibodies in the engineering of chimeric antigen receptor T-cells (CAR-T) and in improving drug delivery to the brain by the enhanced crossing of the blood-brain barrier is also discussed. The pH-responsive antibodies possess strong treatment potential. They emerge as next-generation programmable engineered biologic drugs that are active only within the targeted biological space. Thus, they are valuable in targeting acidified tumor microenvironment because of improved spatial persistence and reduced on-target off-tumor toxicities. We predict that the programmable pH-dependent antibodies become powerful tools in therapies of cancer.

Entities:  

Keywords:  Antibody generation; CAR-T cells; Recycling antibodies; Sweeping antibodies; Tumor microenvironment; pH-responsive antibodies

Mesh:

Substances:

Year:  2021        PMID: 33482842      PMCID: PMC7821552          DOI: 10.1186/s12929-021-00709-7

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  118 in total

1.  Acidic pH increases the avidity of FcgammaR for immune complexes.

Authors:  D H López; A S Trevani; G Salamone; G Andonegui; S Raiden; M Giordano; J R Geffner
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

Review 2.  The blood-brain barrier and its role in immune privilege in the central nervous system.

Authors:  Joel S Pachter; Helga E de Vries; Zsuzsa Fabry
Journal:  J Neuropathol Exp Neurol       Date:  2003-06       Impact factor: 3.685

3.  The year of Pasteur: from the concept of antibody and antigen by Bordet (1895) to the ELISA. What future for immunological diagnosis?

Authors:  J Pillot
Journal:  Clin Diagn Virol       Date:  1996-05

Review 4.  The blood-brain barrier/neurovascular unit in health and disease.

Authors:  Brian T Hawkins; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

5.  Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.

Authors:  Akito Natsume; Mika In; Hiroyuki Takamura; Tomoaki Nakagawa; Yukiko Shimizu; Kazuko Kitajima; Masako Wakitani; So Ohta; Mitsuo Satoh; Kenya Shitara; Rinpei Niwa
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

Review 6.  Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.

Authors:  Jason M Lajoie; Eric V Shusta
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-08       Impact factor: 13.820

7.  "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.

Authors:  Frank A Engler; Joseph Ryan Polli; Tommy Li; Bo An; Michael Otteneder; Jun Qu; Joseph P Balthasar
Journal:  J Pharmacol Exp Ther       Date:  2018-05-07       Impact factor: 4.030

Review 8.  Mouse and human FcR effector functions.

Authors:  Pierre Bruhns; Friederike Jönsson
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

9.  Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.

Authors:  Danlin Yang; Craig Giragossian; Steven Castellano; Marcio Lasaro; Haiguang Xiao; Himanshu Saraf; Cynthia Hess Kenny; Irina Rybina; Zhong-Fu Huang; Jennifer Ahlberg; Tammy Bigwarfe; Maria Myzithras; Erica Waltz; Simon Roberts; Rachel Kroe-Barrett; Sanjaya Singh
Journal:  MAbs       Date:  2017-08-08       Impact factor: 5.857

10.  Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy.

Authors:  Jeffrey C Kang; Wei Sun; Priyanka Khare; Mostafa Karimi; Xiaoli Wang; Yang Shen; Raimund J Ober; E Sally Ward
Journal:  Nat Biotechnol       Date:  2019-04-01       Impact factor: 54.908

View more
  5 in total

Review 1.  Targeting syndecan-1: new opportunities in cancer therapy.

Authors:  Zecheng Yang; Shuaitong Chen; Haoqiang Ying; Wantong Yao
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-18       Impact factor: 5.282

2.  Radiometal-Based PET/MRI Contrast Agents for Sensing Tumor Extracellular pH.

Authors:  Alyssa C Pollard; Jorge de la Cerda; F William Schuler; Tyler R Pollard; Aikaterini Kotrotsou; Federica Pisaneschi; Mark D Pagel
Journal:  Biosensors (Basel)       Date:  2022-02-20

Review 3.  The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates.

Authors:  Seungmin Han; Kwang Suk Lim; Brody J Blackburn; Jina Yun; Charles W Putnam; David A Bull; Young-Wook Won
Journal:  Pharmaceutics       Date:  2022-08-16       Impact factor: 6.525

Review 4.  Tumor acidity: From hallmark of cancer to target of treatment.

Authors:  Alexey Bogdanov; Andrey Bogdanov; Viacheslav Chubenko; Nikita Volkov; Fedor Moiseenko; Vladimir Moiseyenko
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

5.  Tumor pH-Responsive Nanocarriers With Light-Activatable Drug Release for Chemo-Photodynamic Therapy of Breast Cancer.

Authors:  Zhang Zhang; An Gao; Chunyang Sun
Journal:  Front Chem       Date:  2022-06-22       Impact factor: 5.545

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.